Skip to main content

Day: December 9, 2024

Serve Robotics Announces Appointment of Lily Sarafan to its Board of Directors

SAN FRANCISCO, Dec. 09, 2024 (GLOBE NEWSWIRE) — Serve Robotics Inc. (Nasdaq: SERV), a leading embodied AI and automation company, today announced the appointment of Lily Sarafan to its Board of Directors (the “Board”). Sarafan is an accomplished leader with nearly 20 years of experience in entrepreneurship, executive leadership and board governance. She is co-founder and former chief executive of TheKey, one of the largest and most trusted in-home care provider networks, where she serves as executive chair. Sarafan currently serves on the boards of Instacart, Thumbtack and Kyo as well as on the board of trustees of Stanford University. She has been recognized as an EY Entrepreneur of the Year, a Fortune 40 Under 40, Women Health Care Executives’ Woman of the Year, and a Henry Crown Fellow of the Aspen Institute....

Continue reading

Compass Diversified to Host Investor Day on January 16, 2025, in New York City

WESTPORT, Conn., Dec. 09, 2024 (GLOBE NEWSWIRE) — Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle market businesses, today announced that it will host its investor day on Thursday, January 16, 2025, at 9:30am ET at Convene’s One Liberty Plaza location in New York City. The event will include a presentation by CODI’s executive management team followed by a Q&A session, as well as a panel discussion moderated by CODI CEO, Elias Sabo with the CEOs of 5.11 Tactical, PrimaLoft, and Altor Solutions. A summary agenda is provided below. All times in EST.• 9:30am – 10:00am: Participant check-in and continental breakfast• 10:00am – 11:30pm: Compass Diversified presentation and Q&A session• 11:30am – 12:30pm: Moderated panel discussion• 12:30pm – 1:30pm: Lunch and self-guided,...

Continue reading

Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WEST CHESTER, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Verrica’s Compensation Committee granted David Zawitz, Verrica’s new Chief Operating Officer, a nonqualified stock option to purchase 950,000 shares of its common stock under the Company’s Inducement Plan, effective December 9, 2024. The stock option was granted as a material inducement to Mr. Zawitz’s employment with Verrica in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Verrica (or following a bona fide period of non-employment),...

Continue reading

NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer

Investigators concluded that the encouraging oncologic outcomes coupled with a favorable safety profile warrant further evaluation in a randomized trial 23 months median Overall Survival from date of diagnosis was observed in 22 patients with locally advanced or borderline resectable pancreatic cancer US FDA approved protocol amendment to launch new cohort evaluating RT-activated NBTXR3 combined with standard-of-care concurrent chemotherapy and recruitment is ongoing Full data from the completed dose escalation and dose expansion cohorts to be presented at a medical congress in 1H 2025PARIS and CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities...

Continue reading

Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa

CHMP opinion now expected in 1Q 2025 No Major Objections outstanding; continue to expect Germany launch in 2Q 2025 PITTSBURGH, Dec. 09, 2024 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) cancelled the Oral Explanation regarding the Company’s Marketing Authorization Application for beremagene geperpavec-svdt (B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB) that was scheduled for December 6, 2024, and asked the Company to submit written responses to the remaining outstanding issues. There are no Major Objections outstanding from the EMA with respect to the full approval of B-VEC. “We are confident in our ability to address the remaining...

Continue reading

Tim Keating Joins AMD as Senior Vice President, Government Relations and Regulatory Affairs

SANTA CLARA, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) — AMD (NASDAQ: AMD) today announced that Tim Keating has joined the company as senior vice president, Government Relations and Regulatory Affairs, effective today. “Tim is a strong addition to lead our government relations team,” said Ava Hahn, AMD senior vice president, general counsel and corporate secretary. “As high-performance and AI chips play an increasingly larger role in our daily lives over the coming years, Tim’s extensive public policy expertise and deep understanding of regulatory landscapes will play a critical role expanding our engagements with key stakeholders.” Keating has decades of experience, including more than 14 years at Boeing as executive vice president, Government Relations. Before Boeing, he was the senior vice president of Global Government Operations...

Continue reading

Lee Enterprises and ProRata.ai Announce Groundbreaking Content Partnership to Revolutionize Local News and Advertising

DAVENPORT, Iowa, Dec. 09, 2024 (GLOBE NEWSWIRE) — Lee Enterprises, Inc. (NASDAQ: LEE), a leading provider of trusted local journalism across the United States, today announced a first-of-its-kind content partnership with ProRata.ai, an innovator in artificial intelligence-driven solutions. This partnership marks a pivotal milestone in the evolution of hyper-personalized local content and real-time advertising solutions tailored to the unique needs of local search and AI search engines. Through this partnership, Lee Enterprises and ProRata.ai will collaborate on groundbreaking technology integration and co-development efforts to bring a cutting-edge attribution platform to local media. The alliance aims to redefine how local news and advertising are delivered, enabling hyper-personalized content experiences and seamless real-time...

Continue reading

Oil-Dri Announces Record Results for the First Quarter of Fiscal Year 2025

CHICAGO, Dec. 09, 2024 (GLOBE NEWSWIRE) — Oil-Dri Corporation of America (NYSE: ODC), producer and marketer of sorbent mineral products, today announced results for its first quarter of fiscal year 2025.  First Quarter(in thousands, except per share amounts) Ended October 31,  2024 2023 ChangeConsolidated Results      Net Sales $ 127,945 $ 111,438 15  %Operating Income (Including Unallocated Corporate Expenses) $ 21,190 $ 13,156 61  %Net Income $ 16,376 $ 10,742 52  %EBITDA † $ 26,167 $ 17,384 51  %Diluted EPS – Common $       2.25 $       1.50 50  %Business to Business      Net Sales $ 48,415 $ 39,161 24  %Segment Operating Income $ 17,110 $ 11,123 54  %Retail and Wholesale      Net Sales $ 79,530 $ 72,277 10  %Segment Operating Income $ 13,377 $ 11,331 18  %† Please refer...

Continue reading

HealthEquity Reports Third Quarter Ended October 31, 2024 Financial Results

Highlights of the third quarter include:Revenue of $300.4 million, an increase of 21% compared to $249.2 million in Q3 FY24. Net income of $5.7 million, compared to $14.7 million in Q3 FY24, with non-GAAP net income of $69.4 million, an increase of 33% compared to $52.2 million in Q3 FY24. Net income per diluted share of $0.06, compared to $0.17 in Q3 FY24, with non-GAAP net income per diluted share of $0.78, compared to $0.60 in Q3 FY24. Adjusted EBITDA of $118.2 million, an increase of 24% compared to $95.6 million in Q3 FY24. 9.5 million HSAs, an increase of 15% compared to Q3 FY24. Total HSA Assets of $30.0 billion, an increase of 33% compared to Q3 FY24. 16.5 million Total Accounts, including both HSAs and complementary CDBs, an increase of 8% compared to Q3 FY24. The Company repurchased 0.7 million shares of its common stock for...

Continue reading

Nokia Corporation: Repurchase of own shares on 09.12.2024

Nokia CorporationStock Exchange Release9 December 2024 at 22:30 EET Nokia Corporation: Repurchase of own shares on 09.12.2024 Espoo, Finland – On 9 December 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows:Trading venue (MIC Code) Number of shares Weighted average price / share, EUR*XHEL 872,093 4.18CEUX – –BATE – –AQEU – –TQEX – –Total 872,093 4.18* Rounded to two decimals On 22 November 2024, Nokia announced that its Board of Directors is initiating a share buyback program to offset the dilutive effect of new Nokia shares issued to the shareholders of Infinera Corporation and certain Infinera Corporation share-based incentives. The repurchases in compliance with the Market Abuse Regulation (EU) 596/2014...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.